title: Exercise stress testing in healthy subjects during cholinergic stimulation after a single dose of pyridostigmine.
abstract: OBJECTIVE
  The evaluation, by exercise stress testing, of the cardiorespiratory effects of pyridostigmine (PYR), a reversible acetylcholinesterase inhibitor.
  
  
  METHODS
  A double-blind, randomized, cross-over, placebo-controlled comparison of hemodynamic and ventilation variables of 10 healthy subjects who underwent three exercise stress tests (the first for adaptation and determination of tolerance to exercise, the other two after administration of placebo or 45mg of PYR).
  
  
  RESULTS
  Heart rate at rest was: 68+/-3 vs 68+/-3bpm before and after placebo, respectively (P=0.38); 70+/-2 vs 59+/-2bpm, before and after pyridostigmine, respectively (P<0.01). During exercise, relative to placebo: a significantly lower heart rate after PYR at, respectively, 20% (P=0.02), 40% (P=0.03), 80% (P=0.05) and 100% (P=0.02) of peak effort was observed. No significant differences were observed in arterial blood pressure, oxygen consumption at submaximal and maximal effort, exercise duration, respiratory ratio, CO2 production, ventilation threshold, minute ventilation, and oxygen pulse.
  
  
  CONCLUSIONS
  Pyridostigmine, at a dose of 45mg, decreases heart rate at rest and during exercise, with minimal side effects and without interfering with exercise tolerance and ventilation variables.
authors.affiliation: Universidade Federal Fluminense, Niterói e Hospital Pró-Cardiaco, Rio de Janeiro, Brazil.
authors.forename: S M
authors.initials: SM
authors.lastname: Serra
authors.forename: R V
authors.initials: RV
authors.lastname: Costa
authors.forename: B G
authors.initials: BG
authors.lastname: Bastos
authors.forename: K
authors.initials: K
authors.lastname: Bousquet Santos
authors.forename: S H
authors.initials: SH
authors.lastname: Ramalho
authors.forename: A C
authors.initials: AC
authors.lastname: da Nóbrega
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005080:Exercise Test / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D011729:Pyridostigmine Bromide / Q000494:pharmacology*
chemical_list: D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide